BioSyngen Pte Ltd.
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.biosyngen.com
Clinical Trials
8
Active:0
Completed:1
Trial Phases
3 Phases
Early Phase 1:4
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Early Phase 1
4 (50.0%)Phase 1
3 (37.5%)Not Applicable
1 (12.5%)BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
Early Phase 1
Not yet recruiting
- Conditions
- Colorectal CancerPancreatic Cancer
- Interventions
- Biological: Group ABiological: Group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT06645301
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: Single drug group ABiological: Combined treatment group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06643910
- Locations
- 🇨🇳
Yuqing Li, Shenzhen, Guangdong, China
Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma
Early Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: Group ABiological: Group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06645314
A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer
Phase 1
Recruiting
- Conditions
- Locally Advanced Liver Carcinoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 9
- Registration Number
- NCT06526832
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
Early Phase 1
Not yet recruiting
- Conditions
- Locally Advanced/Metastatic Liver Cancer
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT06173726
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
- Prev
- 1
- 2
- Next
News
No news found